CYP17-IN-1 (compound 9c) is a potent and orally active CYP17 inhibitor against rat and human CYP17 with IC50s of 15.8 and 20.1 nM[1]. IC50: 15.8 nM (Rat CYP17), 20.1 nM (Human CYP17)[1]
CYP17-IN-1 (compound 9c) exhibits an IC50 value of 8.5 µM against CYP3A4[1].
CYP17-IN-1 (compound 9c) reduces plasma testosterone level in a dose-dependent manner in Sprague-Dawley rats[1].
[1]. Wang M, et al. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors. Eur J Med Chem. 2017 May 26;132:157-172.